Iovance Biotherapeutics Inc (IOVA)
followers
·
Follow
2 likes
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Frederick G. Vogt |
| Employees: | 500 |
| Web site: | iovance.com |
|
825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
6502607120
| |
| Date | Ratio |
|---|---|
| 2010-04-06 | 24:1 |
| 2013-09-26 | 1:100 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.
Please log in first to see chart